RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation sequencing (NGS) for precise patient stratification and treatment selection in metastatic prostate cancer (mPC).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup